Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

03. Mai 2016 07:30 ET | Quelle: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals to Participate in Bank of America Merrill Lynch Healthcare Conference

RADNOR, Pa., May 03, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and...
02. Mai 2016 07:30 ET | Quelle: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2016 Financial Results

RADNOR, Pa., May 02, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and...
19. April 2016 07:30 ET | Quelle: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals’ Ganaxolone IV Demonstrates Robust Efficacy in Benzodiazepine-Resistant Model of Status Epilepticus

Data Presented at the American Academy of Neurology Annual Meeting Phase 1 Clinical Program On-Track to Initiate in 1H 2016 RADNOR, Pa., April 19, 2016 (GLOBE NEWSWIRE) -- Marinus...
15. April 2016 07:30 ET | Quelle: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone IV to Treat Status Epilepticus

RADNOR, Pa., April 15, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy...
12. April 2016 07:30 ET | Quelle: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals to Present Ganaxolone IV Data at American Academy of Neurology Annual Meeting

RADNOR, Pa., April 12, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy...
07. März 2016 07:30 ET | Quelle: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Provides Business Update and 2015 Financial Results

RADNOR, Pa., March 07, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and...
01. März 2016 07:30 ET | Quelle: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals to Present at the Cowen & Company Annual Healthcare Conference

RADNOR, Pa., March 01, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and...
27. Januar 2016 07:30 ET | Quelle: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals to Participate in Canaccord Genuity Rare Disease Biopharma Day

RADNOR, Pa., Jan. 27, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy...
16. Dezember 2015 07:30 ET | Quelle: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Completes Patient Recruitment in Phase 3 Clinical Trial of Ganaxolone in Focal Onset Seizures

RADNOR, Pa., Dec. 16, 2015 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy...
07. Dezember 2015 09:09 ET | Quelle: Marinus Pharmaceuticals, Inc.

Marinus Presents Additional Responder Analysis Data for Ganaxolone in Focal Onset Seizures at the American Epilepsy Society Annual Meeting

RADNOR, Pa., Dec. 07, 2015 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy...

Vorherige Seite